Corder, Gregory, Tawfik, Vivianne L, Wang, Dong, Sypek, Elizabeth I, Low, Sarah A, Dickinson, Jasmine R, Sotoudeh, Chaudy, Clark, J David, Barres, Ben A, Bohlen, Christopher J, and Scherrer, Gregory
Nature Medicine. Feb 2017, Vol. 23 Issue 2, p164, 10 p.
Cellular signal transduction -- Genetic aspects, Cellular signal transduction -- Health aspects, Drug resistance -- Genetic aspects, Analgesia -- Physiological aspects, Opioids -- Receptors, and Opioids -- Health aspects
Author(s): Gregory Corder [1, 2, 3, 4]; Vivianne L Tawfik [1, 2, 3, 4]; Dong Wang [1, 2, 3, 4]; Elizabeth I Sypek [1, 5]; Sarah A Low [1, 2, [...] Opioid pain medications have detrimental side effects including analgesic tolerance and opioid-induced hyperalgesia (OIH). Tolerance and OIH counteract opioid analgesia and drive dose escalation. The cell types and receptors on which opioids act to initiate these maladaptive processes remain disputed, which has prevented the development of therapies to maximize and sustain opioid analgesic efficacy. We found that [mu] opioid receptors (MORs) expressed by primary afferent nociceptors initiate tolerance and OIH development. RNA sequencing and histological analysis revealed that MORs are expressed by nociceptors, but not by spinal microglia. Deletion of MORs specifically in nociceptors eliminated morphine tolerance, OIH and pronociceptive synaptic long-term potentiation without altering antinociception. Furthermore, we found that co-administration of methylnaltrexone bromide, a peripherally restricted MOR antagonist, was sufficient to abrogate morphine tolerance and OIH without diminishing antinociception in perioperative and chronic pain models. Collectively, our data support the idea that opioid agonists can be combined with peripheral MOR antagonists to limit analgesic tolerance and OIH.